Biotech Daily

Monday July 21, 2025

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH DOWN: GENETIC SIGNATURES UP 12%; PARADIGM DOWN 5%**

*** LUMOS UNAUDITED REVENUE UP 11% TO $19m**

*** ATOMO PLACES $260k OF $728k SHORTFALL; TOTAL SO FAR $2.6m**

*** AMPLIA REQUESTS 'CAPITAL RAISING' HALT**

*** PAINCHEK FILES FINAL FDA DE-NOVO PAIN MONITOR APPLICATION**

*** OSTEOPORE OPENS JAWBONE TRIAL**

*** NYRADA DOSES PHASE I NYR-BI03 BRAIN INJURY, STROKE TRIAL**

*** TRYPTAMINE OPENS PHASE I TRP-8803 PSILOCIN BINGE EATING TRIAL**

*** ANTEOTECH, BLACK DIAMOND BATTERY DEVELOPMENT DEAL**

*** ADVANCE REDUCES TO 5.6% OF OSTEOPORE**

MARKET REPORT

The Australian stock market fell 1.02 percent on Monday July 21, 2025, with the ASX200 down 89.0 points to 8,668.2 points.

Ten of the Biotech Daily Top 40 companies were up, 20 fell, nine traded unchanged and one was untraded. All four Big Caps were down.

Genetic Signatures was the best, up 4.5 cents or 12 percent to 42 cents, with 176,131 shares traded. Medadvisor climbed 10.7 percent; Micro-X was up 9.1 percent; EBR and Proteomics were up more than seven percent; Clinuvel was up 4.5 percent; Nova Eye and Orthocell rose more than three percent; with Clarity and SDI up by less than one percent.

Paradigm led the falls, down two cents or 4.8 percent to 40 cents, with 391,316 shares traded.

Avita, Alcidion and Mesoblast fell more than four percent; Actinogen was down 3.85 percent; Curvebeam, Dimerix, Imugene, Polynovo, Prescient, Pro Medicus and Resonance shed two percent or more; Compumedics, Cyclopharm, Emvision, Immutep, Impedimed, Neuren and Telix were down more than one percent; with Cochlear, CSL, Medical Developments, Nanosonics and Resmed down by less than one percent.

LUMOS DIAGNOSTICS HOLDING

Lumos says unaudited revenue for the year to June 30, 2025 was up 11.4 percent to $US12.4 million ($A19.1 million), compared to the previous corresponding period.
Last year, Lumos said revenue for the year to June 30, 2024 was up 5.7 percent to $US11.1 million (BD: Aug 27, 2024).
Today, the company said receipts from customers for the year to June 30, 2025 were down 61.6 percent to $US6,368,000 ($A9,784,000) compared to the prior year.
Lumos said customer receipts from sales of its Febridx and Viradx respiratory blood tests as well as product development services for the three months to June 30, 20225 fell 75.6 percent to $US1,820,000 compared to the previous corresponding period.
The company said revenue from US Febridx sales for the three months rose 522 percent compared to the prior corresponding period, with sales of Viradx down “due to the end of the ’flu season and increased competition from international supplier”.
Lumos managing-director Doug Ward said the past few months included “a series of very significant milestones that are not only advancing our US regulatory pathway but also laying the foundation for Febridx as a true platform diagnostic”.
“The distribution partnership with Phase Scientific represents the culmination of years of hard work by our exceptional team,” Mr Ward said.
Last week, the company said it had an up-to $US317 million, six-year distribution and supply deal with Hong Kong’s Phase Scientific International Ltd for its Febridx test, subject to receiving a Febridx US Food and Drug Administration clinical laboratory improvement amendments (CLIA)-waiver (BD: Jul 16, 2025).
Today, Lumos said it had a cash burn of $US1,704,000 for the three months, with cash of $US1,956,000 at June 30, 2025 compared to $US6,479,000 at June 30, 2024.
The company said it had $US3,263 in unused finance, giving 3.1 quarters of cash.
Lumos fell 0.3 cents or 4.6 percent to 6.2 cents with 15.6 million shares traded.

ATOMO DIAGNOSTICS

Atomo says it has placed $260,000 of the $727,613 shortfall from its share purchase plan at 1.85 cents a share, taking the total raised to $2,645,388.
Last month, Atomo said it raised $2,113,000 in a placement at 1.85 cents a share and $272,388 of a hoped-for $1.0 million in a share purchase plan, leaving a $727,612.50 shortfall and taking the total to $2,385,388 (BD: Jun 27, 2025).
Today, the company said $260,000 of the shortfall was placed to investors following shareholder approval at its extraordinary general meeting.
Atomo said the shortfall investors would receive one option for every share issued, exercisable at four cents each by July 24, 2028.
The company said the shortfall was managed by Bay Financial and GBA Capital, with the funds to be used for general working capital and ongoing business objectives.
Atomo managing-director John Kelly told Biotech Daily the company had up-to two months to place the remaining shortfall amount of $467,613.
Atomo was unchanged at two cents.

AMPLIA THERAPEUTICS

Amplia has requested a trading halt pending an announcement “regarding a capital raising, to be undertaken by way of a share placement and share purchase plan”.
Trading will resume on July 23, 2025, or on an earlier announcement.
Amplia last traded at 28.5 cents.

PAINCHEK

Painchek says it has submitted the final US Food and Drug Administration de-novo regulatory clearance submission for its adult pain monitoring application.

Last month, Painchek said the FDA required additional clinical study information for de-novo marketing clearance of its pain assessment application (BD: Jun 5, 2024).

Today, the company said it expected “a final decision on the de novo regulatory clearance within 75 days, giving a projected potential clearance date of between late September to early October 2025, if not sooner”.

Painchek said its final submission provided additional information to the FDA collected from its recent US clinical trial “that addressed specific feedback from the regulator”.

Painchek chief executive officer Phillip Daffas said the company was “pleased to have submitted this final documentation to the FDA after the productive discussions we’ve had recently, which again gives us confidence on the pathway to selling the Painchek adult [application] in the US market this year”.

“We’re continuing to lay the groundwork via our established US client relationships, our recently appointed US head of business development and the major integration and reseller partner agreements we’ve established in the region,” Mr Daffas said.

“Combined these will provide us an excellent springboard for rapid US market commercial success upon FDA clearance,” Mr Daffas said.

Painchek was up 0.2 cents or 5.1 percent to 4.1 cents with 1.3 million shares traded.

OSTEOPORE

Osteopore says it has approval for a 10-patient adult trial of its implants for jawbone regeneration at Brisbane’s Princess Alexandra Hospital.

Last month, Osteopore said it would begin a 10-patient, clinical trial of its bio-mimetic scaffolds for maxilla-mandibular, or jaw, reconstruction (BD: Jun 4, 2025).

Today, the company said it had Research Governance Office clearance to conduct the trial, with the first patient expected to be recruited in four weeks.

Osteopore said the trial would study the safety and tolerability of its poly-caprolactone-tri-calcium phosphate (PCL-TCP) scaffold with a vascularized cortico-periosteal tissue transfer, a technique designed to regenerate maxilla and mandible bone.

Osteopore chief executive officer Dr Yujing Lim said the company was “grateful that the necessary approvals have been obtained and that the first patient will soon be recruited to the study”.

“The loss of substantial jawbone is a particularly debilitating condition, and through this study, we hope that the safety and tolerability of our proposed solution may be demonstrated,” Dr Lim said.

Osteopore was up 0.1 cents or 7.7 percent to 1.4 cents with 3.4 million shares traded.

NYRADA

Nyrada says it has dosed the sixth and final cohort, in its phase I trial of Xolatryp, or NYR-BI03, for traumatic brain injury and stroke, with no adverse events reported.

Earlier this year, Nyrada said it had begun recruiting its 40-patient, phase I trial of NYR-BI03 for traumatic brain injury and stroke (BD: Mar 17, 2025).

Today, Nyrada said it had dosed cohort six and “no safety signals, dose-limiting toxicities, or unexpected side effects have been observed throughout the trial”.

The company said final clinical readouts were expected by October 2025.

Nyrada was up 6.5 cents or 22.8 percent to 35 cents with 1.35 million shares traded.

TRYPTAMINE THERAPEUTICS (FORMERLY EXOPHARM)

Tryptamine says it has opened recruitment for its 12-patient, phase I trial of TRP-8803 intra-venous psilocin for binge eating disorder at Melbourne's Swinburne University.
Last month, Tryptamine said it had ethics approval to begin the open-label study of TRP-8803 with psychotherapy for adults with binge eating disorder (BD: Jun 23, 2025).
Previously, the company said that psilocin was the active psychedelic metabolite of psilocybin found in 'magic mushrooms' (BD: Jul 1, 2024).
Today, Tryptamine said the trial would be conducted in two six-person cohorts, with each cohort administered doses of TRP-8803 14 days apart in a monitoring setting and following preparatory psychotherapy.
The company said Swinburne University had received "a number of in-bound enquiries from potential trial participants and prospective patient screening is expected to commence shortly".
Tryptamine said high level results were expected by 2026.
Tryptamine was unchanged at 3.3 cents with 2.4 million shares traded.

ANTEOTECH

Anteotech says it has a joint development agreement with the Austin, Texas-based Black Diamond Structures to produce and commercialize its Anteo X 'cross linker' battery.
Anteotech said the product would combine its 'cross linker' Anteo X battery with Black Diamond's single and multi-walled Molecular Rebar carbon nano-tube dispersion technology into a high silicon lithium-ion battery.
The company said the users of the combined Anteo X and Molecular Rebar product would "be battery manufacturers incorporating greater than 10 percent silicon by weight active material in their anodes".
Anteotech said that the parties had agreed on "technical and commercial milestones to be achieved within defined timeframes focused on early sales and sales growth".
The company said the milestones included "the delivery of Anteo X to Texas for joint production, sample supply to targeted customers, as well as the establishment of logistics and quality control arrangements".
Anteotech did not disclose the commercial terms.
Anteotech was up 0.3 cents or 23.1 percent to 1.6 cents with 29.3 million shares traded.

OSTEOPORE

Advance Opportunities Fund says it has reduced its substantial shareholding in Osteopore from 16,245,909 shares (9.96%) to 11,491,915 shares (5.55%).
The Cayman Islands-based Advance said that sold 4,753,994 shares between July 16, 17 and 18, 2025 for a total of $65,652, or 1.4 cents a share.
Last year, Osteopore said that it expected to raise $20 million from Advance for a redeemable convertible note at four percent interest a year, issuing in four equal tranches of 20 equal sub-tranches of $250,000 each, converting at 80 percent of the average closing price on "any five consecutive days" as selected by the noteholder during the 45 business days immediately preceding the conversion date (BD: Sep 27, 2024).